Compare Baxter International Inc (BAX) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Msci Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Msci Inc trades at $611.43 (market cap $44.51B). The key difference: Msci Inc is far larger — about 4× Baxter International Inc's market cap, and Msci Inc pays the higher dividend (1.34%). Which is the better fit depends on your goals.
| BAX | MSCI | |
|---|---|---|
Market Cap | $11.26B | $44.51B |
Sector | Health | Financials |
52-Week High | $29.22 | $643.83 |
52-Week Low | $15.80 | $511.84 |
Enterprise Value | $18.93B | $50.68B |
Dividend Yield | 0.92% | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
MSCI trades at $620.23, up 2.57% with bullish technical signals and strong earnings beats. The company shows robust fundamentals with 2025 revenue of $3.13B and net income of $1.20B, supported by high margins. Recent news highlights strategic partnerships with UBS and acquisitions to enhance private markets and climate risk capabilities, reinforcing growth prospects amid positive analyst sentiment.
Outlook remains positive with a consensus price target of $718.14, though elevated P/E of 35.42 and high debt levels pose valuation and financial risks. Earnings growth and strategic expansions are key catalysts, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
